Watch MAIA. Know when insiders buy.
One email the day a filing lands. Free.
Work order
72
PASS · insiders 65, shorts 79
Insiders, 90 days
+$203K
net buying · 5 buys, 0 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $80.3MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$26.8MNET CASH $052W 0.87 – 2.95SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$8.3M | −$7.9M | — | -0.13 | −$6.8M | — | — | Aug 10 |
| Q1 2026 · Mar 31 | — | — | — | −$6.9M | −$6.4M | — | -0.14 | −$5.3M | — | — | Aug 10 |
| Q4 2025 · Dec 31derived | — | — | — | −$4.3M | −$3.6M | — | -0.08 | −$7M | — | — | Mar 23 |
| Q3 2025 · Sep 30 | — | — | — | −$9.4M | −$8.9M | — | -0.27 | −$3.5M | — | — | Nov 7 |
| Q2 2025 · Jun 30 | — | — | — | −$5.2M | −$5.3M | — | -0.18 | −$4.1M | — | — | Aug 10 |
| Q1 2025 · Mar 31 | — | — | — | −$5.4M | −$4.5M | — | -0.16 | −$4.2M | — | — | Aug 10 |
| Q4 2024 · Dec 31derived | — | — | — | −$5M | −$3.6M | — | -0.12 | −$3.9M | — | — | Mar 23 |
| Q3 2024 · Sep 30 | — | — | — | −$4.2M | −$2.7M | — | -0.11 | −$3.5M | — | — | Nov 7 |
| Q2 2024 · Jun 30 | — | — | — | −$3.8M | −$8.9M | — | -0.40 | −$4.7M | — | — | Nov 7 |
| Q1 2024 · Mar 31 | — | — | — | −$3.9M | −$8.1M | — | -0.46 | −$3.6M | — | — | Nov 7 |
| Q4 2023 · Dec 31derived | — | — | — | −$6.4M | −$6.3M | — | -0.41 | −$4M | — | — | Mar 21 |
| Q3 2023 · Sep 30 | — | — | — | −$5M | −$4.9M | — | -0.36 | −$3.2M | — | — | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$24.3M | −$22.4M | — | -0.70 | −$18.8M | — | — | — | — |
| FY2024 · to Dec 31 | $0 | — | −$17M | −$23.3M | — | -1.05 | −$15.7M | — | — | — | — |
| FY2023 · to Dec 31 | $0 | — | −$20.2M | −$19.8M | — | -1.49 | −$13.1M | — | — | — | — |
| FY2022 · to Dec 31 | $0 | — | −$16.2M | −$15.8M | — | -1.75 | −$12.1M | — | — | — | — |
| FY2021 · to Dec 31 | — | — | −$7.8M | −$12.6M | — | -2.37 | −$4.1M | — | — | — | — |
Every number comes from MAIA Biotechnology, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.